159 related articles for article (PubMed ID: 38338686)
21. High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC).
Moreno M; Bontkes HJ; Scheper RJ; Kenemans P; Verheijen RH; von Mensdorff-Pouilly S
Cancer Lett; 2007 Nov; 257(1):47-55. PubMed ID: 17692456
[TBL] [Abstract][Full Text] [Related]
22. An anti-MUC1-antibody-interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells.
Heuser C; Ganser M; Hombach A; Brand H; Denton G; Hanisch FG; Abken H
Br J Cancer; 2003 Sep; 89(6):1130-9. PubMed ID: 12966437
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.
Knudson KM; Hicks KC; Alter S; Schlom J; Gameiro SR
J Immunother Cancer; 2019 Mar; 7(1):82. PubMed ID: 30898149
[TBL] [Abstract][Full Text] [Related]
24. Anti-MUC1-C Antibody-Conjugated Nanoparticles Potentiate the Efficacy of Fractionated Radiation Therapy.
Detappe A; Mathieu C; Jin C; Agius MP; Diringer MC; Tran VL; Pivot X; Lux F; Tillement O; Kufe D; Ghoroghchian PP
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1380-1389. PubMed ID: 32634545
[TBL] [Abstract][Full Text] [Related]
25. TA-MUC1 as detected by the fully humanized, therapeutic antibody Gatipotzumab predicts poor prognosis in cervical cancer.
Heublein S; Friese K; Kost B; Marmé F; Kuhn C; Mahner S; Dannecker C; Mayr D; Jeschke U; Vattai A
J Cancer Res Clin Oncol; 2018 Oct; 144(10):1899-1907. PubMed ID: 30062487
[TBL] [Abstract][Full Text] [Related]
26. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2
Chu Y; Nayyar G; Jiang S; Rosenblum JM; Soon-Shiong P; Safrit JT; Lee DA; Cairo MS
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34244307
[TBL] [Abstract][Full Text] [Related]
27. Repression of MUC1 Promotes Expansion and Suppressive Function of Myeloid-Derived Suppressor Cells in Pancreatic and Breast Cancer Murine Models.
Sahraei M; Bose M; Sanders JA; De C; DasRoy L; Nath S; Brouwer CR; Mukherjee P
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070449
[TBL] [Abstract][Full Text] [Related]
28. Full-length recombinant antibodies from
Rashid MH
MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
[TBL] [Abstract][Full Text] [Related]
29. Epithelial mucin-1 (MUC1) expression and MA5 anti-MUC1 monoclonal antibody targeting in multiple myeloma.
Burton J; Mishina D; Cardillo T; Lew K; Rubin A; Goldenberg DM; Gold DV
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3065s-3072s. PubMed ID: 10541345
[TBL] [Abstract][Full Text] [Related]
30. Treatment of pancreatic ductal adenocarcinoma with tumor antigen specific-targeted delivery of paclitaxel loaded PLGA nanoparticles.
Wu ST; Fowler AJ; Garmon CB; Fessler AB; Ogle JD; Grover KR; Allen BC; Williams CD; Zhou R; Yazdanifar M; Ogle CA; Mukherjee P
BMC Cancer; 2018 Apr; 18(1):457. PubMed ID: 29685122
[TBL] [Abstract][Full Text] [Related]
31. Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody.
Fallon JK; Vandeveer AJ; Schlom J; Greiner JW
Oncotarget; 2017 Mar; 8(13):20558-20571. PubMed ID: 28423552
[TBL] [Abstract][Full Text] [Related]
32. Effect of desialylation on binding, affinity, and specificity of 56 monoclonal antibodies against MUC1 mucin.
Dai J; Allard WJ; Davis G; Yeung KK
Tumour Biol; 1998; 19 Suppl 1():100-10. PubMed ID: 9422094
[TBL] [Abstract][Full Text] [Related]
33. Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments.
Moreno-Vicente J; Willoughby JE; Taylor MC; Booth SG; English VL; Williams EL; Penfold CA; Mockridge CI; Inzhelevskaya T; Kim J; Chan HTC; Cragg MS; Gray JC; Beers SA
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017153
[TBL] [Abstract][Full Text] [Related]
34. Targeting the human MUC1-C oncoprotein with an antibody-drug conjugate.
Panchamoorthy G; Jin C; Raina D; Bharti A; Yamamoto M; Adeebge D; Zhao Q; Bronson R; Jiang S; Li L; Suzuki Y; Tagde A; Ghoroghchian PP; Wong KK; Kharbanda S; Kufe D
JCI Insight; 2018 Jun; 3(12):. PubMed ID: 29925694
[TBL] [Abstract][Full Text] [Related]
35. An antibody-drug conjugate targeting a GSTA glycosite-signature epitope of MUC1 expressed by non-small cell lung cancer.
Pan D; Tang Y; Tong J; Xie C; Chen J; Feng C; Hwu P; Huang W; Zhou D
Cancer Med; 2020 Dec; 9(24):9529-9540. PubMed ID: 33084221
[TBL] [Abstract][Full Text] [Related]
36. Staining of MUC1 in ovarian cancer tissues with PankoMab-GEX detecting the tumour-associated epitope, TA-MUC1, as compared to antibodies HMFG-1 and 115D8.
Dian D; Lenhard M; Mayr D; Heublein S; Karsten U; Goletz S; Kuhn C; Wiest I; Friese K; Weissenbacher T; Jeschke U
Histol Histopathol; 2013 Feb; 28(2):239-44. PubMed ID: 23275306
[TBL] [Abstract][Full Text] [Related]
37. Anti-tumor effect of the anti-KL-6/MUC1 monoclonal antibody through exposure of surface molecules by MUC1 capping.
Doi M; Yokoyama A; Kondo K; Ohnishi H; Ishikawa N; Hattori N; Kohno N
Cancer Sci; 2006 May; 97(5):420-9. PubMed ID: 16630141
[TBL] [Abstract][Full Text] [Related]
38. A novel multifunctional anti-CEA-IL15 molecule displays potent antitumor activities.
Liu Y; Wang Y; Xing J; Li Y; Liu J; Wang Z
Drug Des Devel Ther; 2018; 12():2645-2654. PubMed ID: 30214153
[TBL] [Abstract][Full Text] [Related]
39. Specific Targeting of Zinc Transporter LIV-1 with Immunocytokine Containing Anti-LIV-1 VHH and Human IL-2 and Evaluation of its
Dehghan R; Parikhani AB; Cohan RA; Shokrgozar MA; Mirabzadeh E; Ajdary S; Zeinali S; Ghaderi H; Talebkhan Y; Behdani M
Curr Pharm Des; 2024; 30(11):868-876. PubMed ID: 38482625
[TBL] [Abstract][Full Text] [Related]
40. Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors.
Wingert S; Reusch U; Knackmuss S; Kluge M; Damrat M; Pahl J; Schniegler-Mattox U; Mueller T; Fucek I; Ellwanger K; Tesar M; Haneke T; Koch J; Treder M; Fischer W; Rajkovic E
MAbs; 2021; 13(1):1950264. PubMed ID: 34325617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
